Annu Singh1, Shakeel Modak2, Armand K Solano1, Brian H Kushner2, Suzanne Wolden3, Joseph Huryn1, Cherry L Estilo1. 1. Dental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: Although metastatic involvement of bony sites including cranial bones is common in neuroblastoma (NB), mandibular metastases (MM) are uncommon, and specific outcomes have not been reported upon in the modern therapeutic era. METHODS: In this retrospective study, medical records on patients with MM from NB were reviewed. Statistical analysis was performed using the Kaplan-Meier method. RESULTS: Of 29 patients, nine (31%) had MM at diagnosis, whereas in 20 (69%) MM were first detected at NB relapse at a median time of 26 (6-89) months from diagnosis. Median maximal diameter of lesions was 3 (range 0.8-4.9) cm. MM were unilateral in 83% of patients, with ascending ramus (55%) and mandibular body (38%) being the two most common sites. All patients received systemic chemotherapy, and 26 (93%) patients received radiotherapy to MM. At a median follow-up of 37.3 (24.2-219.5) months, eight of nine patients with MM at diagnosis did not experience mandibular progressive disease. Eighteen of 20 patients with MM at relapse received therapeutic radiotherapy; objective responses were noted in 78%. Seventy-two percent (5/18) had not experienced relapse within the radiation field at a median of 12 (2-276) months postradiotherapy. Dental findings at follow-up after completion of NB therapy included hypodontia, hypocalcification of enamel, and trismus. Median 3-year overall survival in patients with relapsed MM was 51 ± 12% months from relapse. CONCLUSION: MM when detected at diagnosis is associated with a prognosis similar to that for other skeletal metastases of NB. Radiotherapy is effective for control of MM detected both at diagnosis and relapse. Significant dental abnormalities posttherapy warrant regular dental evaluations and appropriate intervention.
BACKGROUND: Although metastatic involvement of bony sites including cranial bones is common in neuroblastoma (NB), mandibular metastases (MM) are uncommon, and specific outcomes have not been reported upon in the modern therapeutic era. METHODS: In this retrospective study, medical records on patients with MM from NB were reviewed. Statistical analysis was performed using the Kaplan-Meier method. RESULTS: Of 29 patients, nine (31%) had MM at diagnosis, whereas in 20 (69%) MM were first detected at NB relapse at a median time of 26 (6-89) months from diagnosis. Median maximal diameter of lesions was 3 (range 0.8-4.9) cm. MM were unilateral in 83% of patients, with ascending ramus (55%) and mandibular body (38%) being the two most common sites. All patients received systemic chemotherapy, and 26 (93%) patients received radiotherapy to MM. At a median follow-up of 37.3 (24.2-219.5) months, eight of nine patients with MM at diagnosis did not experience mandibular progressive disease. Eighteen of 20 patients with MM at relapse received therapeutic radiotherapy; objective responses were noted in 78%. Seventy-two percent (5/18) had not experienced relapse within the radiation field at a median of 12 (2-276) months postradiotherapy. Dental findings at follow-up after completion of NB therapy included hypodontia, hypocalcification of enamel, and trismus. Median 3-year overall survival in patients with relapsed MM was 51 ± 12% months from relapse. CONCLUSION: MM when detected at diagnosis is associated with a prognosis similar to that for other skeletal metastases of NB. Radiotherapy is effective for control of MM detected both at diagnosis and relapse. Significant dental abnormalities posttherapy warrant regular dental evaluations and appropriate intervention.
Authors: Prasad L Gawade; Melissa M Hudson; Sue C Kaste; Joseph P Neglia; Louis S Constine; Leslie L Robison; Kirsten K Ness Journal: Pediatr Blood Cancer Date: 2013-11-01 Impact factor: 3.167
Authors: Alexei L Polishchuk; Richard Li; Christine Hill-Kayser; Anthony Little; Randall A Hawkins; Jeffrey Hamilton; Michael Lau; Hung Chi Tran; Caron Strahlendorf; Richard S Lemons; Vivian Weinberg; Katherine K Matthay; Steven G DuBois; Karen J Marcus; Rochelle Bagatell; Daphne A Haas-Kogan Journal: Int J Radiat Oncol Biol Phys Date: 2014-05-24 Impact factor: 7.038
Authors: Robert F Dempsey; Daniel C Chelius; William C Pederson; Marco Maricevich; Amy L Dimachkieh; Michael E Kupferman; Howard L Weiner; Larry H Hollier; Edward P Buchanan Journal: Clin Plast Surg Date: 2019-01-30 Impact factor: 2.017
Authors: Dana L Casey; Ken L Pitter; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2018-01-09 Impact factor: 7.038
Authors: Adepitan A Owosho; Paul Brady; Suzanne L Wolden; Leonard H Wexler; Cristina R Antonescu; Joseph M Huryn; Cherry L Estilo Journal: Pediatr Hematol Oncol Date: 2016-09-30 Impact factor: 1.969
Authors: Erika A Newman; Shahab Abdessalam; Jennifer H Aldrink; Mary Austin; Todd E Heaton; Jennifer Bruny; Peter Ehrlich; Roshni Dasgupta; Reto M Baertschiger; Timothy B Lautz; Daniel S Rhee; Max R Langham; Marcus M Malek; Rebecka L Meyers; Jaimie D Nathan; Brent R Weil; Stephanie Polites; Mary Beth Madonna Journal: J Pediatr Surg Date: 2018-09-19 Impact factor: 2.545
Authors: Asad Ullah; Atbin Doroodchi; Luis Velasquez Zarate; Samantha N Mattox; Taylor Sliker; Dorian K Willhite; Jaffar Khan; Harry C Owen; Surendra K Rajpurohit; Nikhil G Patel; Robyn M Hatley Journal: Int J Environ Res Public Health Date: 2021-04-14 Impact factor: 3.390